This website stores cookies on your device. These cookies are used to improve our website and provide more personalized services to you.
To find out more about the cookies we use, see our Privacy Policy.

AcceptDecline
 menu

​MDxHealth and Maastricht University collaborate on next generation (epi)genetic cancer diagnostics

may 8, 2017

MDxHealth announced that it has signed an agreement with the Faculty of Health, Medicine and Life Sciences / School for Oncology and Developmental Biology (GROW) at Maastricht University to expand its existing research collaboration to develop commercial next generation (epi)genetic cancer diagnostics.

Under the terms of the multi-year R&D agreement, the collaboration will focus on developing (epi)genetic-based assays to provide better insight in the diagnosis, staging and treatment of cancer patients. For these next generation assays, the focus will be on sample in and result out based platforms. This technology would also be applied to MDxHealth's current and upcoming liquid biopsy tests including SelectMDx(TM) for Prostate Cancer.

"GROW at Maastricht University are true visionaries and we are fortunate to have such a long-standing and collaborative relationship," said Dr. Jan Groen, CEO of MDxHealth. "The development of next generation liquid biopsy diagnostics for oncology will be game-changing and help physicians manage their patients faster and more effectively."

"As a thought-leader in epigenetics, MDxHealth is the ideal partner to collaborate on next generation (epi)genetic diagnostics," said Prof. Dr. Manon van Engeland, Professor of Pathobiology of Cancer and Scientific Vice-Director of GROW. "MDxHealth's expanding portfolio of liquid biopsy tests are ideal to run on the assays we're in the process of developing."

"We are delighted that MDxHealth is joining our science business community at the Brightlands Maastricht Health Campus," said Jan Cobbenhagen, CEO of the Brightlands Maastricht Health Campus. "MDxHealth fits perfectly in our thriving ecosystem of startups, SMEs, multinationals and renowned knowledge institutions.''

About GROW

GROW is the School for Oncology and Developmental Biology at the Maastricht University Medical Centre (MUMC+), The Netherlands, and accredited by the Royal Academy of Arts and Sciences (KNAW). GROW focuses on research and teaching of (epi)genetic and cellular concepts, as well as (micro)environmental factors underlying normal and abnormal development. With a strong emphasis on translational research, scientists and clinicians within GROW aim at implementing basic knowledge into innovative approaches for individualizing prevention, patient diagnostics and treatment of cancer. More information about GROW is available at http://www.grow-um.nl.

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.


  overview news & events

Want to stay up to speed with the latest from Brightlands? Register for our newsletter?

Sign me up!